Abstract
Background
The global population is aging at an accelerated rate. There is a lack of data on the burden of varicella and herpes zoster in adults aged 65 years and older.
Objective
This study assesses the global burden of varicella and herpes zoster among adults aged 65 and older from 1992 to 2021.
Methods
We used Global Burden of Disease (GBD) 2021 to identify the number and rates of incidence and disability-adjusted life years (DALYs) of varicella and herpes zoster in adults aged 65 and older.
Results
From 1992 to 2021, The age-standardized incidence rate (ASIR) of varicella and herpes zoster increased among adults aged 65 years and older, while the age-standardized death rate (ASDR) decreased. There were differences in the burden of varicella-zoster among adults aged 65 years and older by among sexes, ages, and regions. The health inequalities analysis showed an improvement among countries.
Conclusion
From 1992 to 2021, the global burden of varicella zoster among adults aged 65 and older has changed significantly. The ASIR of varicella and herpes zoster increased, but ASDR decreased. Despite the notable advancement in health equity across countries, the burden persists disproportionately among populations in low-SDI regions.
Highlights
What is already known about this topic?
Herpes zoster is a common dermatological disease in adults aged 65 years and older. Few studies have assessed the global burden of varicella and herpes zoster in adults aged 65 years and older.
What does this study add?
This study shows that the global incidence of varicella and herpes zoster increased, and DALYs decreased in adults aged 65 years and older from 1992 to 2021. The burden persists disproportionately among populations in low SDI regions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 General Hospital of Northern Theater Command, Department of Dermatology, Liaoning, China
2 Kebei Hospital of Shaoxing (Wu Jieping Urology Center of Shaoxing), Department of Health Management Center, Zhejiang, China (GRID:grid.461944.a) (ISNI:0000 0004 1790 898X)
3 General Hospital of Northern Theater Command, Department of Dermatology, Liaoning, China (GRID:grid.461944.a)